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Patients with cystic ﬁbrosis (CF) are at increased risk of some Material and methods 
cancers. Little is known about the cancer risks among carriers het­ 14 
erozygous for the CF mutation and it is hypothesized this may be We used the National Inpatient Register, which records infor­
associated with reduced cancer risk. Using Swedish general popula­ mation on date of discharge and diagnoses according to the ICD 
tion-based registers, we identiﬁed 884 patients with CF from 1968 codes, to identify patients with a diagnosis of CF in Sweden 
to 2003 and 3,033 of their ﬁrst-degree relatives The subjects were between 1968 and 2003 (ICD-8 code 273.0; ICD-9 code 277.0; 
followed from birth of index persons or 1958, whichever came later, and ICD-10 code E84). As, CF patients rarely live beyond 60 
until death, emigration or 2003, whichever came ﬁrst. Cancer risks 
  
15 years of age, we included only those who were aged 60 years or 
were compared with the general Swedish population using standar­
less at follow-up, to improve the speciﬁcity of a CF diagnosis dized incidence ratios (SIR) with 95% conﬁdence intervals (CI). 
from this register, although the effect of    Patients, followed for an e of 21 excludingaverag ars, were at a such patientsye  higher over­
          
was investigated. In Sweden, all inpatient care is public and tax-all risk of cancer. Some 26 cancer diagnoses, after excluding multi­
ple diagnoses of nonmelanoma skin cancer in one man, produced funded, private practice in this area is almost nonexistent. The 
an overall SIR of 3.2 (95% CI 2.1–4.6). We found statistically signif­ Multi-Generation Register allows linkage between parents and 
icantly increased risks for kidney, thyroid, endocrine, lymphoma children born in Sweden from 1932 or later and alive in 1961. The 
and nonmelanoma skin cancer. There was no modiﬁcation of cancer coverage that mainly depends on the year of birth of the index-
risk among parents and siblings, with an average of 21 years of fol­
         
16 individual is on average close to 90% of all parents. This register 
low-up. This study did not identify a heterozygote advantage for CF was used to identify both biological parents, as well as siblings of 
gene mutations in relation to cancer risk. 
the patients. The Swedish Migration and Death registers provided ' 2009 UICC 
information on date of migration or death among index subjects, 
their parents and siblings. The National Swedish Cancer Register, 
Key words: cystic ﬁbrosis; gene mutation; cancer; risk established in 1958 and reportedly more than 98% complete,17
was used to identify the date and diagnosis of cancer among index 
Improvements in the management of cystic ﬁbrosis (CF), over subjects, their parents and siblings. All data were linked using the 
the last 3 decades, have resulted in markedly improved survival unique personal identity number issued to all Swedish residents 
and the number of patients surviving to adulthood is increasing. alive in 1947 or subsequently. 
Few studies have indicated an increased risk of certain cancers Using the Swedish Inpatient Register, 884 CF patients were 
among these patients, although some of these studies may be lim­ diagnosed between 1968 and 2003
1–6
    (Table I). Through register 
ited by short follow-up time and concerns about selection  bias. linkage, we identiﬁed 761 biological fathers and 777 biological 
With an estimated prevalence of 1/25–1/40 heterozygosity for mothers corresponding to some 86% of the total number of poten­
CF gene mutations is common, yet little studied. Compared with tially eligible parents. Failure to identify parents was mainly 
 those, who do not carry a mutation, heterozygosity is associated because patients or their parents were born before 1932.16 We also 
with reduced expression of the CF transmembrane conductance obtained data on 1,495 siblings of CF patients. 
   
7 regulator (CFTR) gene product, but not with clinical symptoms This study was approved by the Karolinska Institutet regional 
of CF. The reason for the high prevalence of CF gene mutations ethics committee. 
worldwide is unclear. It has been hypothesized that heterozygosity 
for CF gene mutations would offer an advantage through 
improved protection against infectious disease. Support for this Statistical analysis 
theory has come from in vitro studies of gastrointestinal infectious 
8,9 The standardized incidence ratio (SIR), the ratio of the observed agents. Since the etiology of many gastrointestinal tumors is to the expected number of cancers in the cohort, was used as a 
thought to involve an infectious agent,10 or as a late consequence 
11 measure of relative risk. The expected number of cancer diagnoses of chronic inﬂammatory activity, it is plausible that CF hetero­ was calculated by adding all person-years accumulated in the 
zygosity could also confer some degree of cancer protection, par­ cohort divided into strata deﬁned by sex, age (in 5-year groups) 
ticularly gastrointestinal tract cancers. Indeed, in a gene-study of and calendar year of observation (in 5-year intervals) and then 
cancer patients in Wales, patients with colorectal cancer had a 
lower than expected  
multiplying the stratum-speciﬁc person-time by the corresponding 
prevalence of CF gene mutations.12 Increased stratum-speciﬁc incidence rates for the entire Swedish population.
fertility is another suggested heterozygote advantage that could In the calculation of these incidence rates the denominator was 
account for the high prevalence of CF gene mutations. However, 
13 estimated as the number of individuals in the mid-year population there are no epidemiological data to support this hypothesis.
Due to autosomal recessive inheritance, all parents and two-
third of nondiseased siblings of patients with CF are heterozygous 
for a CF mutation. To our knowledge, no previous general popula­
 tion-based study has investigated cancer risk among ﬁrst-degree 
         relatives of patients with CF. In this general population-based
study, with long follow-up time, we investigated overall and site-
speciﬁc cancer risk in a cohort of patients with CF, as well as can­
cer risk among their parents and siblings. 
˚
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TABLE I – CHARACTERISTICS OF STUDY POPULATION 
CF patients Fathers Mothers Siblings 
Total number 884 
Sex 
Male % 52.3 
Mean follow-up, years 21.4 
Mean year of entry/Exit 1979/2000 
Mean age at exit, years 24.2 
Mean age at diagnosis of cancer, years 
All cancers 40.4 
Digestive cancers 52.5 
Others 39.1 
761 
– 
21.1 
1979/2000 
55.3 
64.2 
63.7 
64.5 
777 
– 
22.2 
1979/2001 
52.7 
54.8 
65.8 
53.1 
1,495 
49.9 
21.8 
1980/2002 
26.2 
35.9 
– 
35.9 
TABLE II – RELATIVE RISK OF CANCER, OVERALL AND BY TYPE, AMONG 884 SWEDISH PATIENTS WITH
 
CYSTIC FIBROSIS 1968–2003, COMPARED WITH SWEDISH GENERAL POPULATION
 
Cancer type ICD7 Obs./Exp. SIR (95% CI) 
Cancer in any site1 140–209 26/8.21 3.2 (2.1–4.6) 
Digestive Cancer 150–159 4/0.71 5.6 (1.5–14.4) 
Colorectal Cancer 153–154 2/0.42 4.8 (0.6–17.3) 
Biliary passage and liver cancer 155 1/0.08 12.8 (0.3–71.2) 
Pancreatic cancer 157 1/0.06 15.7 (0.4–87.5) 
Trachea, bronchus, lung cancer 162 1/0.23 4.3 (0.1–24.0) 
Testis cancer 178 1/0.39 2.6 (0.07–14.5) 
Kidney cancer 180 3/0.21 14.0 (2.9–40.9) 
Urinary organ cancer excluding kidney 181 1/0.14 7.0 (0.2–39.2) 
Thyroid cancer 194 2/0.2 9.8 (1.2–35.5) 
Endocrine cancer 195 3/0.25 12.0 (2.5–35.0) 
Lymphoma 200–202,205 5/0.68 7.3 (2.4–17.11) 
Nonmelanoma skin cancer1 191 3/0.13 23.3 (4.8–68.2) 
1One of the patients had multiple diagnoses of nonmelanoma skin cancer and we included only the ﬁrst 
diagnosis of nonmelanoma skin cancer for this patient. 
without previously reported cancer. The 95% conﬁdence intervals 
(CI) were calculated assuming that the observed events followed a 
Poisson distribution. 
The cohorts were followed from 1958, when the Cancer Regis­
ter was established, or from birth of index persons, or immigration 
if this occurred subsequently until the date of emigration, death or 
until December 31, 2003, whichever occurred ﬁrst. Follow-up for 
the younger siblings started from their birth date, immigration or 
1958, whichever occurred last. We excluded all benign tumors 
and cancers found incidentally at autopsy. 
In an additional analysis, we restricted our data to those patients 
who received a diagnosis of cystic ﬁbrosis (n 5 664) as hospital 
inpatients on 2 separate occasions to ensure diagnostic accuracy. 
We also performed stratiﬁed analyses for CF patients where the 
age at follow-up was below age 20 years, 20–39 years or over age 
39 years. Another stratiﬁed analysis was by calendar year of hos­
pital admission (before or after 1989). We also investigated the 
effect of excluding patients who lived beyond age 60 years, by 
reanalyzing the data without age restriction. 
All analyses were conducted using SAS statistical software. 
Results 
Cystic ﬁbrosis patients 
The 884 patients with CF were followed for an average of 21.4 
years. During the follow-up period, 41 cancers were observed in 
24 individuals compared with 8.22 expected, corresponding to a 
SIR of 5.0 (95% CI 3.6–6.8). However, 1 patient had multiple 
diagnoses of nonmelanoma skin cancer, and to prevent a dispro­
portionate inﬂuence on the results, we repeated the analysis 
including only the ﬁrst nonmelanoma skin cancer diagnosis; and 
the risk estimate for overall cancers was somewhat reduced to 3.2 
(95% CI 2.1–4.6), but remained statistically signiﬁcant (Table II). 
There was an increased risk for cancers of the digestive system 
(SIR 5 5.6; 95% CI 1.5–14.4, n 5 4). There were statistically sig­
niﬁcant increased risks for cancers of the kidney, thyroid, endo­
crine (3 adrenal malignancies), lymphoma and nonmelanoma skin 
cancers. 
A total of 33 patients with CF underwent lung transplantation 
and 3 of them developed cancer (1 lymphoma, 1 nonmelanoma 
skin cancer and 1 thyroid cancer) compared with 0.39 expected, 
corresponding to a SIR of 7.6 (95% CI 1.6–22.3). Among the 
patients without lung transplantation, 23 cancers were observed 
compared with 7.75 expected, corresponding to a SIR of 3.0 (95% 
CI 1.9–4.5). The mean age at diagnosis of cancer was 40.4 years 
(with a range from 2.3 to 59.8 years). We observed 4 childhood 
cancers including 2 patients with lymphoma and 2 with cancers of 
the kidney. 
Analysis restricted to those who received a diagnosis of cystic 
ﬁbrosis on at least 2 separate occasions as hospital inpatients 
resulted in a SIR of 3.8 (95% CI 2.2–6.1). Stratiﬁcation by age at 
follow-up found a consistently increased cancer risk among all 
strata compared with the general population rate, with SIRs (and 
95% CI) of 5.1 (1.4–13.0), 2.3 (0.8–4.9), and 3.0 (1.7–5.0) for fol­
low-up at ages under 20, 20–39, and over 39 years, respectively. 
In stratiﬁed analysis by calendar year of hospital admission 
(before or after 1989), we observed a statistically signiﬁcant 
increased overall cancer risk in both periods: for 1968–1988 
SIR 5 3.3 (95% CI 1.8–5.5) and for 1989–2003 SIR 5 2.8 (95% 
CI 1.4–5.0). When we included those who lived beyond age 
60 years, the risk estimate for overall cancer was 1.7 (1.3–2.0). 
First-degree relatives 
The 761 biological fathers and 777 biological mothers of CF 
patients were followed for an average of 21 years. During the fol­
low-up period, 133 cancers were observed in 119 individuals, 
compared with 137.44 expected (SIR 5 1.0, 95% CI 0.8–1.2) (Ta­
ble III). Thus, there was no association with cancer risk among 
parents. In the site-speciﬁc analyses, the only statistically signiﬁ­
cant association was an increased risk of esophageal cancer 
(SIR 5 4.7, 95% CI 1.5–10.9, n 5 5), all in fathers, 2 of squamous 
cell type and 3 with unspeciﬁed histology). 
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TABLE III – RELATIVE RISK OF CANCER, OVERALL AND BY TYPE, AMONG 1,538 PARENTS AND 1,495 SIBLINGS OF PATIENTS WITH CYSTIC FIBROSIS 
1968–2003, COMPARED WITH SWEDISH GENERAL POPULATION 
Cancer type 
Parents Siblings 
Obs./Exp. SIR (95% CI) Obs./Exp. SIR (95% CI) 
Cancer in any site 133/137.44 1.0 (0.8–1.2) 21/19.59 1.1 (0.7–1.6) 
Digestive cancer 26/25.57 1.0 (0.7–1.5) 0/2.01 0 (0–1.8) 
Esophageal cancer 5/1.07 4.7 (1.5–10.9) 0/0.07 0 (0–50.0) 
Stomach cancer 3/4.05 0.7 (0.2–2.2) 0/0.25 0 (0–14.7) 
Colorectal cancer 14/13.79 1.0 (0.6–1.7) 0/1.19 0 (0–3.1) 
Biliary passage and liver cancer 1/2.55 0.4 (0.01–2.2) 0/0.20 0 (0–18.7) 
Pancreatic cancer 2/3.04 0.7 (0.1–2.4) 0/0.20 0 (0–18.7) 
Trachea, bronchus, lung cancer 11/9. 68 1.1 (0.6–2.0) 2/0.75 2.7 (0.3–9.6) 
Breast cancer 23/22.48 1.0 (0.7–1.5) 3/3.50 0.9 (0.2–2.5) 
Cervix uteri cancer 3/3.17 1.0 (0.2–2.8) 2/0.75 2.7 (0.3–9.6) 
Corpus uteri cancer 3/3.77 0.8 (0.2–2.3) 0/0.33 0 (0–11.1) 
Ovarian cancer 2/3.85 0.5 (0.1–1.9) 2/0.61 3.3 (0.4–11.9) 
Prostate cancer 15/15.82 1.0 (0.5–1.6) 1/0.67 1.5 (0.04–8.3) 
Testis cancer 0/1.03 0 (0 – 3.6) 3/0.76 4.0 (0.8–11.6) 
Kidney cancer 1/3.84 0.3 (0.01–1.5) 0/0.43 0 (0–8.6) 
Urinary organ cancer excluding kidney 5/5.99 0.8 (0.3–2.0) 0/0.42 0 (0–8.7) 
Brain cancer 6/5.3 1.1 (0.4–2.5) 5/1.98 2.5 (0.8–5.9) 
Thyroid cancer 2/1.46 1.4 (0.2–5.0) 0/0.46 0 (0–8.1) 
Endocrine cancer 1/2.81 0.4 (0.01–2.0) 0/0.57 0 (0–6.5) 
Lymphoma 4/5.28 0.8 (0.2–1.9) 0/1.37 0 (0–2.7) 
Melanoma skin cancer 9/6.30 1.4 (0.7–2.7) 1/1.51 0.7 (0.02–3.7) 
Non melanoma skin cancer 4/4.78 0.8 (0.2–2.1) 0/0.38 0 (0–9.8) 
Among the 1,495 siblings of CF patients, who were followed 
for an average of 21 years, 21 cancers were observed while 19.59 
were expected (SIR 5 1.1, 95% CI 0.7–1.6) (Table III). Again 
indicating a lack of association with cancer in ﬁrst-degree relatives 
of those with CF. We did not ﬁnd any statistically signiﬁcant can­
cer risks among the site-speciﬁc cancers studied in siblings of CF 
patients. 
Analysis restricted to ﬁrst-degree relatives of those patients who 
received a CF diagnosis on at least 2 separate occasions, to ensure 
diagnostic accuracy, showed no conspicuous variation in the 
results (data not shown). 
Discussion 
This general population-based study with essentially unbiased 
long-term follow-up suggests that patients with CF are at an ele­
vated overall risk of cancer. We also conﬁrmed the previously 
reported higher risk of digestive tract cancers. In this study, we 
also investigated the risk of cancer among ﬁrst-degree relatives 
likely to be heterozygous for CF polymorphisms and did not ﬁnd 
any signiﬁcant increased or decreased overall cancer risk. 
The increased occurrence of gastrointestinal cancer among 
patients with CF, in our study, is consistent with results from pre­
vious studies.1–6 We also observed statistically signiﬁcant 
increased risks of cancers of the kidney, thyroid, endocrine, lym­
phoma and nonmelanoma skin cancer. Patients with CF are 
exposed to X-ray examinations repeatedly at an early age. This is 
one potential explanation for higher risk of cancers of the thy-
roid,18 kidney19 and bone.20 Studies of individuals exposed to 
radiation for treatment and of Japanese atomic bomb survivors 
suggested a causal association between ionizing radiation and can­
cers of thyroid and kidney. The thyroid gland is highly sensitive to 
ionizing radiation especially at younger ages.18 The increased risk 
of lymphoma could be secondary to post-transplant immune-sup­
pression.2 However, only one of the patients with lymphoma had a 
report of lung transplantation. It is also worth emphasizing that CF 
patients have a substantial exposure to antibiotics over their life, 
especially aminoglycosides. Surveillance bias, due to the intensive 
medical follow-up of CF patients, could also be responsible for 
the observed higher risk of some site-speciﬁc cancers such as the 
thyroid cancer. As the number of site-speciﬁc cancers was small, 
chance could be other explanation for these ﬁndings. It has been 
shown that the increased risk of cancer might be more pronounced 
in CF patients who underwent lung transplantation.2 In our study, 
we observed a higher relative risk among those who had lung 
transplantation, although this ﬁnding was based on small numbers. 
A signiﬁcant excess cancer risk remained among those who were 
not transplant recipients. 
It has been argued that the high prevalence of heterozygosity 
for CF gene mutations could be explained by some advantages 
that this confers, such as improved defense against infections, par­
ticularly in the gastrointestinal tract.8,9 Credence for this hypothe­
sis has been lent by results from in vitro studies showing that the 
entry of infectious agents into epithelial cells is impaired in ani­
mals heterozygous for CF polymorphisms.9 Due to the autonomic 
recessive inheritance of CF, both parents of an affected child are 
heterozygous (or homozygous) for a CF gene mutation. In this 
study, we did not ﬁnd any signiﬁcant change in the risk of cancer 
among individuals heterozygous for CF gene mutations. Lowen­
fels et al.21 estimated cancer risk among relatives of CF patients 
using self-reported information. They found a 50% reduction in 
smoking-related cancers among parents of cystic ﬁbrosis patients, 
but they did not observe any increase or decrease in overall cancer 
risk, which is consistent with the results of this study. However, 
we did not conﬁrm the reduced risks for smoking-related cancers. 
Our ﬁnding of a signiﬁcant excess risk of esophageal cancer is not 
consistent with our a priori hypothesis and may represent a chance 
ﬁnding. Padua et al.12 investigated the rate of the DF508 mutation 
among 1,765 patients with a diagnosis of malignant melanoma, 
myelodysplasia, acute myeloid leukemia, lymphoma, colon or 
breast cancer and compared it with the DF508 mutation rate 
among 301 hospital-based controls. The results indicated a lower 
than expected prevalence of heterozygosity among patients with 
colorectal cancer and malignant melanoma.12 In our study, these 
reduced risks were not conﬁrmed. In contrast with earlier 
22,23reports, we observed that the risk of breast cancer in mothers 
and sisters was close to unity, suggesting that heterozygosity for 
CF is unrelated to breast cancer risk. 
Strengths of this study include its general population-based set­
ting with a study population encompassing virtually all known CF 
cases in Sweden from 1968 to 2003, and the complete and long 
follow-up using Swedish registries such as the Swedish Cancer 
Registry. Information from the Swedish Multi-Generation register 
made it possible to identify and follow ﬁrst-degree relatives of CF 
patients. The Swedish Cancer Register with more than 98% com­
pleteness17 ensured the validity of the outcome. 
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Our study had some limitations. Although we used information 
on all individuals diagnosed with CF in Sweden over a long period 
of time, the number of diagnosed patients per year was relatively 
small and for those that were young at the end of the study period, 
the statistical power to estimate risk was limited. We were able to 
identify only 86% of the parents of index subjects. In our study, 
the assumption that ﬁrst-degree relative status indicates hetero­
zygosity is valid for the vast majority of parents, but might be sub­
ject to misclassiﬁcation among siblings, moving any association 
toward the null. Therefore, the results of cancer risk among sib­
lings should be interpreted with greater caution as they may under­
estimate an association, if it exists. Although the DF508 mutation 
is by far the most common in CF, we did not have individual in­
formation on mutation-type, so some type-speciﬁc effects may not 
have been identiﬁed here. Patients with CF were identiﬁed through 
diagnoses recorded in medical registers, the validity of which is 
generally high. Error from diagnostic misclassiﬁcation, if any, is 
likely to move relative risks toward unity thus potentially underes­
timating the magnitude of associations. Another possibility is that 
some non-CF patients, such as polycystic kidney disease or cystic 
thyroid nodules, who may be misclassiﬁed as having CF might 
have excess cancer risk which could explain the observed 
increased overall cancer risk. However, to increase diagnostic 
speciﬁcity, we also restricted the analyses to those who received at 
a diagnosis of CF on at least 2 separate hospital admissions. The 
results from these subanalyses of patients with greater diagnostic 
certainty suggest that our ﬁndings are not due to diagnostic inac­
curacy. 
In conclusion, patients with CF are at an overall excess risk of 
cancer and particularly for cancers of the digestive tract, kidney, 
thyroid, endocrine, lymphoma and nonmelanoma skin cancer. We 
did not observe a statistically signiﬁcant risk reduction among het­
erozygous gene mutation carriers. 
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